[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-multiple-myeloma-rrmm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-multiple-myeloma-rrmm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100649825","neurocognitive-trajectories-after-bcma-car-t-100649825",false,"NCT07740317","Neurocognitive Trajectories After BCMA CAR-T","Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma","CAR-T Cog","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign an IRB-approved informed consent\n2. Ability to retain independent decision-making capacity as per the enrolling investigator\n3. Age ≥ 18 years of age at the time of consent\n4. Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician\n5. Ability to read and understand the English language\n6. ECOG 0-2\n7. If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician\n8. Reliable access to internet access; a tablet, laptop and\u002For desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report\n9. Ability to complete required assessments, as determined by the treating clinician\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) disease\n2. Known neurodegenerative disease or major neurocognitive disorder\n3. Stroke and\u002For traumatic brain injury (TBI) within 12 months\n4. Concurrent investigational neuroactive drugs","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).",[25,26,27],"Multiple Myeloma (MM)","CART Therapy","Refractory Multiple Myeloma (RRMM)",[29],"cancer","NOT_YET_RECRUITING","2026-07-28",{"date":33,"type":34},"2026-07-31","ACTUAL",{"date":36,"type":21},"2026-09",{"date":38,"type":21},"2029-11",{"name":40,"class":41},"Wake Forest University Health Sciences","OTHER"]